HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Moderna Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Moderna Intelligence Report

Generated from 5 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Aug 1, 2026

Confidence

Moderate Confidence · 75%

Evidence

16 items

Sources

8

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Moderna maintains an active intelligence profile across Infectious Disease, Vaccine, Oncology, Non-small Cell Lung Cancer, HPV-related cancers. 5 signals are linked with 2 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 75% across 2 tracked sources. Highest-priority development: FDA Approves First Generics of Gilotrif (afatinib) Tablets. Regulatory precedent. Why this matters: provides agency context on approval that may shape timing or evidence expectations for Moderna.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 17, 2026

    E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice

    Oncology · HPV-related cancers · opportunity score 37

    View detail
  2. investigateJun 16, 2026

    NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273

    Infectious Disease · COVID-19 · opportunity score 37

    View detail
  3. regulatory

    FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    Drug Trials Snapshots

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — SANDIMMUNE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 187 with buyer quality 9 (Mid-Market). Competitive pressure: Low. Portfolio impact: High. 2 investigate-priority signals warrant near-term portfolio review.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Drug Trials Snapshots

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SANDIMMUNE (SUPPL)

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SANDIMMUNE (SUPPL)

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna

    Oncology · Non-small Cell Lung Cancer

  • E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice

    Oncology · HPV-related cancers

  • NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273

    Infectious Disease · COVID-19

  • mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years

    Infectious Disease · Vaccine

  • Moderna initiates safety and immunogenicity study for RSV vaccines in infants

    Infectious Disease · Vaccine

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.